Navigation Links
Discovery suggests new combination therapy strategy for basal-like breast cancers
Date:5/21/2012

CHAPEL HILL, N.C. Multiple research projects including a 2006 study conducted at the University of North Carolina at Chapel Hill have used DNA microarray analysis to identify several breast cancer subtypes, including luminal A, luminal B, basal-like and HER2-enriched. Simple tests are being developed to help doctors identify these subtypes and to treat their patients in a more biologically-based way. In turn, these tests have made several studies possible that indicate that basal-like, or triple negative breast cancer, is more prevalent in African Americans than their Caucasian counterparts.

A new study led by UNC Lineberger scientist Charles Perou, PhD, and Sean Egan, PhD, from The Hospital for Sick Children in Toronto, Ontario, demonstrates that deletion of a sugar transferase called LFNG (nicknamed "lunatic fringe"), promotes cell proliferation and tumor formation of basal-like breast cancers. The study was published last week in the journal Cancer Cell.

In a laboratory model, the deletion of LFNG not only caused tumors to form but also activated two cellular signaling pathways thought to be important in tumor formation. The team found increased activation of both notch signaling (a receptor found on the surface of cells that is involved in stem cell differentiation and development) and increased expression of the Met oncogene.

Taking the laboratory model a step further, the team examined these same genes and signaling pathways in basal-like tumors and found the same genetic signature.

"This is exciting because there are drugs in development that target each of these pathways. While targeting each pathway alone might work, our findings suggest that combination therapy could be a promising strategy for treating these basal-like tumors," says Dr. Perou, who is the May Goldman Shaw Distinguished Professor of Molecular Oncology and professor of genetics, and pathology and laboratory medicine at the UNC School of Medicine.

Basal-like breast cancer tends to be more aggressive and have a poorer prognosis than other types, making up about 15 percent of all breast cancers. In young African-American women who develop breast cancer, the subtype makes up about 39 percent of all diagnoses. It is primarily treated with chemotherapy, although newer targeted drugs are being tested in clinical trials.


'/>"/>
Contact: Ellen de Graffenreid
edegraff@med.unc.edu
919-962-3405
University of North Carolina Health Care
Source:Eurekalert

Related medicine news :

1. Researchers make promising discovery in pursuit of effective lymphoma treatments
2. Scientists make breakthrough in bile duct cancer with discovery of new gene mutations
3. H1N1 discovery paves way for universal flu vaccine: UBC research
4. Feelings of immaturity accompany alcohol misuse into adulthood; discovery could improve treatments
5. Discovery could help to develop drugs for organ transplant and cancer patients
6. Washingtons Life Sciences Discovery Fund awards commercialization grants
7. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
8. New discovery of proteins involved in positioning muscular nuclei
9. Cell signaling discovery provides new hope for blood disorders
10. Gene mutation discovery sparks hope for effective endometriosis screening
11. Discovery predicts patient sensitivity to important drug target in deadly brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health ... partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is to ... Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. Food ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate about ... what is often a very difficult and challenging time.” , A Certified Medical ...
(Date:3/24/2017)... ... , ... “End Time GPS”: a dauntless and enlightened study of the ... is the creation of published author, Wesley Gerboth, a World War II veteran, with ... projects. Now, at age ninety-one, he shares the Wisdom God bestowed upon him in ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... collection of inspiring stories about real people of God in congregations across the ... John Miller, a Presbyterian minister ordained in 1964 who has served congregations in ...
(Date:3/23/2017)... & Seattle, WA (PRWEB) , ... March 23, 2017 , ... ... health emergency and now estimates that there could be four million Zika-related cases in ... epidemics to date with numbers of US cases reported per year skyrocketing to an ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... DUBLIN , Mar. 24, 2017 Research and ... (IPF) Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with ... Corporation, Merck & Co., Inc., Biogen and Sanofi are involved in the ... candidates, of which one is in Phase III stage, 15 are in ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... their offering. ... provides separate comprehensive analytics for the US, Canada , ... Asia-Pacific , Latin America , and Rest of ... 2022. Also, a six-year historic analysis is provided for these markets. Market ...
(Date:3/24/2017)... , March 23, 2017  Provectus Biopharmaceuticals, Inc. ... "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, ... Financing Commitment Term Sheet (the "Definitive Financing") it ... of the Company,s stockholders, who are referred to ... a Form 8-K filed with the Securities and ...
Breaking Medicine Technology: